GCANRx is a clinical stage biopharmaceutical company focused on the development and commercialization of an innovative pharma-grade therapeutic that reduces disruptive symptoms in patients suffering from neuropsychiatric disorders without the side effects of existing medications. GCANRx has teamed up with a world renowned research center to treat 100 children diagnosed with ASD and related behavioral problems, with a combination of CBD, and additional proprietary compounds for up to 24 weeks. The purpose of the double-blind, placebo controlled study is to prove the efficacy of a new therapeutic in treating the core symptoms of Autism (ASD).
| Website | http://www.gcanrx.com |
| Employees | 1 (0 on RocketReach) |
| Founded | 2018 |
| Address | 15 Walker Ave, Baltimore, Maryland, US |
| Phone | +1 954-985-3838 |
| Technologies |
HTML
,
Font Awesome
,
G Suite
+6 more
(view full list)
|
| Industry | Biotechnology Research, Cannabis Technology, Biotechnology, Biopharmaceutical, Delivery Systems |
| Keywords | Biopharmaceutical, Neuropsychiatric Disorders, Clinical Stage, Drug Development, Pharmaceutical Research, Mental Health, Biotechnology, Clinical Trials, Brain Health, Prescription Drugs, Patient Care, Healthcare, Pharma |
Looking for a particular GCANRx employee's phone or email?
GCANRx is based in Baltimore, Maryland.